食管鳞状细胞癌的癌症免疫疗法现状
Current status of cancer immunotherapy for esophageal squamous cell carcinoma.
作者信息
Kono Koji, Mimura Kousaku, Yamada Reo, Ujiie Daisuke, Hayase Suguru, Tada Takeshi, Hanayama Hiroyuki, Min Aung Kyi Thar, Shibata Masahiko, Momma Tomoyuki, Saze Zenichirou, Ohki Shinji
机构信息
Department of Gastrointestinal Tract Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Department of Advanced Cancer Immunotherapy, Fukushima Medical University, Fukushima, Japan.
出版信息
Esophagus. 2018 Jan;15(1):1-9. doi: 10.1007/s10388-017-0596-2. Epub 2017 Nov 27.
BACKGROUND
Immunotherapy has become a promising treatment strategy for cancer. Immune checkpoint blockade with anti-CTLA4 mAb and anti-PD-1 mAb has demonstrated clear evidence of objective responses including improved overall survival and tumor shrinkage, driving renewed enthusiasm for cancer immunotherapy in multiple cancer types including esophageal squamous cell carcinoma (ESCC). There are several clinical trials using anti-PD1 mAb for ESCC in early phases and the results are currently promising.
RESULTS AND CONCLUSIONS
In this review, recent advances in cancer immunotherapy for ESCC are discussed with particular focus on immune checkpoint inhibitors and cancer vaccine.
背景
免疫疗法已成为一种有前景的癌症治疗策略。使用抗CTLA4单克隆抗体和抗PD-1单克隆抗体进行免疫检查点阻断已显示出明确的客观反应证据，包括改善总生存期和肿瘤缩小，这重新激发了人们对多种癌症类型（包括食管鳞状细胞癌（ESCC））的癌症免疫疗法的热情。目前有多项使用抗PD1单克隆抗体治疗ESCC的早期临床试验，结果很有前景。
结果与结论
在本综述中，我们讨论了ESCC癌症免疫疗法的最新进展，特别关注免疫检查点抑制剂和癌症疫苗。
Zotero 插件